| Prev Close | 84.68 |
| Open | 84.97 |
| Day Low/High | 84.08 / 85.06 |
| 52 Wk Low/High | 66.10 / 87.35 |
| Volume | 5.12M |
| Avg Volume | 8.26M |
Merck & Co. Inc. (MRK)
84.53
0.15
0.18
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.56B |
| Market Cap | 214.56B |
| EPS | 2.30 |
| P/E Ratio | 39.53 |
| Div & Yield | 2.20 (2.59%) |
Cramer: Got the Apple-FANG Blues? Look for a Rotation
There's one going on now.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
'Date' These Potential Biotech Winners
As with Adamas Pharmaceuticals, circling key milestone dates on your calendar can prove beneficial.
Cramer: August Finally Arrives
There are plenty of reasons for the selloff, not the least of which is White House chaos.
President Trump Has Disbanded His Manufacturing Council
Pressure is mounting on CEOs to step down from President Donald Trump's American Manufacturing Council
CEOs Dump Donald Trump
CEOs exit President's Council after Charlottesville response
Daily Market Preview: CEOs Dump Trump & Activists Stir the Danone Pot
CEOs exit President's Council after Charlottesville response
North Korea Dials Down Tensions With United States, Stocks Higher
North Korea says it will delay a decision on attacking Guam.
Rev's Forum: Bears' Fundamental Arguments Lose Out to Price Patterns
The problem for the pessimists is the same one that has plagued them since the election -- the price action is not cooperating.
Cramer: This Is Why You Keep Cash on Hand
Because the selloff isn't over.
President Trump Condemns Hate Groups, Days After Charlottesville Attack
Days after the deadly attack in Charlottesville, President Trump comes out with his strongest condemnation yet of the hate groups who rallied there.
Jim Cramer on Merck, Bitcoin, Nvidia, Netflix, Disney, Procter & Gamble, TJX and Home Depot
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer analyzes Monday's trending stocks.
Jim Cramer on Merck CEO Ken Frazier: Everyone Has a Right to Speak Their Mind
Merck CEO Ken Frazier is leaving Trump's business council.
Cramer: FANG and the Lessons of History
What a difference 2 years make -- or 17.
Merck Is Benefiting From Keytruda, but Jim Cramer Prefers Eli Lilly
Merck vs. Eli Lilly.
Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks.
Does Merck's Rally Have Legs?
MRK has shaped up on the charts.
Cramer: Stop Talking About the 'Market'
It just isn't as useful or descriptive right now.
4 Undervalued Biotech Stocks
Two are turnaround stories, and two are oversold.
47 Quarterly Dividend Declared By Merck
Merck , said today that its board of directors authorized a quarterly dividend of 47 cents
Cramer: Let Loose the Growth Hounds
Day 2 of the selloff brings in an entirely new kind of buyer.
Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street
Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.
Merck Ready to Resume Long-Term Uptrend
The price momentum and money flow indicators of the drug maker are in positive alignment.
Blue-Chip Breakouts: Intel, Boeing, and Merck Are Ready to Spring Higher in May
These three big stocks are teetering on the edge of breakout territory to start the month.
The Good, the Bad and the Ugly (Late Afternoon Edition)
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have I might be trading some of the earnings reports that will be released ...
Wake Up Wall Street: Trump Considers Breaking Up Big Banks
Trump suggested he could split their consumer businesses from investment operations
2 'Swing for the Fences' Small Biotechs
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
2 'Swing for the Fences' Small Biotechs
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
Surveying the NASH Drug Landscape
Biotech investors should keep a close eye on the progress in this huge potential market.
Takeaways and Observations (Early Edition)
"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...
